Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Other Events

ME Staff 8-k
-
0

Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Other Events
Item 8.01 Other Events.

On June 21, 2017, Supernus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that its partner Shire has received U.S. Food and Drug Administration approval for MydayisTM, a once-daily treatment comprised of three different types of drug-releasing beads for patients 13 years and older with Attention Deficit Hyperactivity Disorder. Shire expects to make Mydayis commercially available in the United States in the third quarter of 2017. Based on the agreement between the Company and Shire, Shire will pay to the Company a single digit percentage royalty on net sales of the product.

A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following document is furnished as an Exhibit  to Item 8.01 hereof:

Exhibit 99.1 — Press Release Dated June 21, 2017.




SUPERNUS PHARMACEUTICALS INC Exhibit
EX-99.1 2 a17-15638_1ex99d1.htm EX-99.1 Exhibit 99.1     Supernus Announces that its Partner Shire Receives FDA Approval for Mydayis™ for ADHD   Rockville,…
To view the full exhibit click here
About Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company’s neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Recent Trading Information

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) closed its last trading session down -0.15 at 44.00 with 686,153 shares trading hands.